Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 10/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616520 | 0.87 | KMT2A (0.70) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL28388705 | 0.86 | KMT2A (0.64) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL3620745 | 0.84 | KMT2A (0.65) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL2643864 | 0.84 | KMT2A (0.68) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL29793669 | 0.84 | KMT2A (0.68) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL6506088 | 0.84 | KMT2A (0.62) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL3613079 | 0.82 | HCAR3 (0.72) | KMT2AMAPTNPSR1HCAR3 | |
| SCHEMBL11707399 | 0.82 | KMT2A (0.62) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL9137225 | 0.80 | KMT2A (0.76) | KMT2AMAPTNPSR1ALDH1A1HCAR3 | |
| SCHEMBL28126362 | 0.80 | KMT2A (0.57) | KMT2AMAPTNPSR1ALDH1A1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| CN-104072486-B | As the connection-1H-benzoglyoxaline of hepatitis C virus inhibitors | SQUIBB BRISTOL MYERS CO. (US) | 2016-04-06 | — | — | CN | disclosed |
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| CN-103153986-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-11-05 | — | — | CN | disclosed |
| CN-104072486-A | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO | 2014-10-01 | — | — | CN | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| WO-2010017401-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017401-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-2046336-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008011045-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1597249-A1 | ANTHELMINTIC AGENTS AND INSECTICIDAL COMPOSITIONS | Pharmacia & Upjohn Company LLC (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004074272-A1 | ANTHELMINTIC AGENTS AND INSECTICIDAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040171650-A1 | Novel anthelmintic and insecticidal compositions | LEE BYUNG HYUN (US) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | KMT2A 4516/4885MAPT 4065/4885NPSR1 4040/4885 |
| US-20040171650-A1 | Novel anthelmintic and insecticidal compositions | ACHE, AADAC, BCHE | KMT2A 1734/4885MAPT 2335/4885NPSR1 4297/4885 |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP2 | KMT2A 2333/4885MAPT 4637/4885NPSR1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.